Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)

NCT03608033 is registered in ClinicalTrials.gov with Omeros Corporation as lead sponsor.

NCT NCT03608033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03608033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)
Lead sponsor
Omeros Corporation
Phase
Phase 3
Overall status
Terminated
Start date
April 5, 2018
Completion date
January 12, 2024
Enrollment
360 (actual)
Sites
139

Conditions

As the registry lists them; a condition with its own page is linked.

iga nephropathy